CYDX (Cyduct Diagnostics) Scaled Net Operating Assets: (As of . 20)


What is Cyduct Diagnostics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cyduct Diagnostics's operating assets for the quarter that ended in . 20 was $ Mil. Cyduct Diagnostics's operating liabilities for the quarter that ended in . 20 was $ Mil. Cyduct Diagnostics's Total Assets for the quarter that ended in . 20 was $ Mil. Therefore, Cyduct Diagnostics's scaled net operating assets (SNOA) for the quarter that ended in . 20 was .

Cyduct Diagnostics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Scaled Net Operating Assets Chart

Cyduct Diagnostics Annual Data
Trend
Scaled Net Operating Assets

Cyduct Diagnostics Quarterly Data
Scaled Net Operating Assets

CYDX vs SECI, QTXB, ASNB: Scaled Net Operating Assets Comparison

For the Medical Devices subindustry, Cyduct Diagnostics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyduct Diagnostics Scaled Net Operating Assets vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyduct Diagnostics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Cyduct Diagnostics's Scaled Net Operating Assets falls into.


Cyduct Diagnostics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cyduct Diagnostics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in . 20 is calculated as

Scaled Net Operating Assets (SNOA)(A: . 20 )
=(Operating Assets (A: . 20 )-Operating Liabilities (A: . 20 ))/Total Assets (A: . 20 )
=(-)/
=

where

Operating Assets(A: . 20 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(A: . 20 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

Cyduct Diagnostics's Scaled Net Operating Assets (SNOA) for the quarter that ended in . 20 is calculated as

Scaled Net Operating Assets (SNOA)(Q: . 20 )
=(Operating Assets (Q: . 20 )-Operating Liabilities (Q: . 20 ))/Total Assets (Q: . 20 )
=(-)/
=

where

Operating Assets(Q: . 20 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(Q: . 20 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.